Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

Arsalan Rafiq; Tausif Chughtai; Umair Ashraf; Yash Patel; Farbod Raiszadeh; Eduard Sklyar; Maryam Afshar; Jonathan N. Bella; Gayathri Kamalakkannan

doi:10.1016/j.ihj.2020.06.015

Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

Arsalan Rafiq, Tausif Chughtai, Umair Ashraf, Yash Patel, Farbod Raiszadeh, Eduard Sklyar, Maryam Afshar, Jonathan N. Bella, Gayathri Kamalakkannan

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

Original language	English (US)
Pages (from-to)	296-298
Number of pages	3
Journal	Indian Heart Journal
Volume	72
Issue number	4
DOIs	https://doi.org/10.1016/j.ihj.2020.06.015
State	Published - Jul 1 2020

Keywords

Myocardial perfusion imaging
QTc interval prolongation
Regadenoson

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Divisions

Pulmonary, Critical Care and Sleep Medicine

Access to Document

10.1016/j.ihj.2020.06.015

Cite this

@article{96e0da0954ec49d99a9e3ba7e711851c,

title = "Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging",

abstract = "The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.",

keywords = "Myocardial perfusion imaging, QTc interval prolongation, Regadenoson",

author = "Arsalan Rafiq and Tausif Chughtai and Umair Ashraf and Yash Patel and Farbod Raiszadeh and Eduard Sklyar and Maryam Afshar and Bella, \{Jonathan N.\} and Gayathri Kamalakkannan",

note = "Publisher Copyright: {\textcopyright} 2020 Cardiological Society of India",

year = "2020",

month = jul,

day = "1",

doi = "10.1016/j.ihj.2020.06.015",

language = "English (US)",

volume = "72",

pages = "296--298",

journal = "Indian Heart Journal",

issn = "0019-4832",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

AU - Rafiq, Arsalan

AU - Chughtai, Tausif

AU - Ashraf, Umair

AU - Patel, Yash

AU - Raiszadeh, Farbod

AU - Sklyar, Eduard

AU - Afshar, Maryam

AU - Bella, Jonathan N.

AU - Kamalakkannan, Gayathri

PY - 2020/7/1

Y1 - 2020/7/1

N2 - The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

AB - The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.

KW - Myocardial perfusion imaging

KW - QTc interval prolongation

KW - Regadenoson

UR - https://www.scopus.com/pages/publications/85087834648

UR - https://www.scopus.com/inward/citedby.url?scp=85087834648&partnerID=8YFLogxK

U2 - 10.1016/j.ihj.2020.06.015

DO - 10.1016/j.ihj.2020.06.015

M3 - Article

C2 - 32861387

AN - SCOPUS:85087834648

SN - 0019-4832

VL - 72

SP - 296

EP - 298

JO - Indian Heart Journal

JF - Indian Heart Journal

IS - 4

ER -

Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

Abstract

Keywords

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this